GO
Loading...

Valeant planning hostile bid for Allergan

Botox by Allergan
Jb Reed | Bloomberg | Getty Images
Botox by Allergan

Valeant plans to take a buyout offer for Allergan directly to its shareholders this week, as the Botox maker continues to rebuff its proposals that have risen as high as $53 billion.

Valeant Pharmaceuticals International Chairman and CEO J. Michael Pearson said in a conference call Tuesday that proxies seeking support for its bid may be mailed in "the near-term."

Read MoreAckman and Valeant plot 'not fair': Gabelli

"It is clear Allergan's management and their board will never sit down and act in the interest of their shareholders," he said.

Canadian-based Valeant has teamed with Bill Ackman's Pershing Square Capital Management to try to purchase Allergan. The two companies went public with their takeover attempt in April and have increased their offer several times.

Allergan Inc. has repeatedly rejected the offers as underpriced and risky. But Pearson said that Valeant believes an Allergan shareholder vote would "be overwhelmingly in support of the deal."

Valeant and Pershingwhich has a 9.7 percent stake in Allerganhave continued to pursue Allergan despite the Irvine, California company's disinterest. The latest offer was worth about $53 billion. Allergan's market capitalization was about $47.5 billion in Tuesday morning trading.

Ackman previously said he would move to replace most of Allergan's board of directors as part of the battle for control of the company. Pearson said Tuesday that Pershing is looking to call a special shareholders meeting to remove six of Allergan's nine board members. Last week Pershing filed a lawsuit to confirm that its push for the special meeting won't trigger a defensive "poison pill" from Allergan.

Read MoreAllergan board says Valeant bid undervalues company

Allergan adopted a one-year shareholder rights plan after Valeant and Pershing announced their bid in April. Under the plan, if any person or group acquires a 10 percent or greater stake in the company, other stock owners would be allowed to acquire additional shares at a discounted rate.

Pearson said that a special meeting of Allergan shareholders could be held in August, but should take place by year's end.

An e-mail to Allergan for comment was not immediately returned.

Allergan's stock added 29 cents to $159.66 in morning trading Tuesday (click here for the latest quote), while shares of Valeant fell 47 cents to $117.28 (click here for the latest Valeant quote).

By The Associated Press

Symbol
Price
 
Change
%Change
VRX
---
AGN
---

Featured

Contact M&A

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More